

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

Original Issue Date (Created):	July 9, 2003
Most Recent Review Date (Revised):	January 28, 2014
Effective Date:	April 1, 2014

I. POLICY

Transesophageal endoscopic gastroplasty is considered **investigational** as a treatment of gastroesophageal reflux disease (e.g., the EndoCinch procedure)

Transesophageal radiofrequency to create submucosal thermal lesions of the gastroesophageal junction (i.e., the Stretta procedure) is considered **investigational** as a treatment of gastroesophageal reflux disease.

Endoscopic submucosal implantation of a prosthesis or injection of a bulking agent (e.g., biocompatible liquid polymer, polymethylmethacrylate beads, zirconium oxide spheres) is considered **investigational** as a treatment of gastroesophageal reflux disease.

There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with the procedures identified above.

II. PRODUCT VARIATIONS

[N] = No product variation, policy applies as stated

[Y] = Standard product coverage varies from application of this policy, see below

[N] Capital Cares 4 Kids

[N] Indemnity

[N] PPO

[N] SpecialCare

[N] HMO

[N] POS

[Y] SeniorBlue HMO**

[Y] FEP PPO*

[Y] SeniorBlue PPO**

*Refer to FEP Medical Policy Manual MP-2.01.38 Transesophageal Endoscopic Therapies for Gastroesophageal Reflux Disease. The FEP Medical Policy manual can be found at: www.fepblue.org

** Refer to Novitas Solutions Local Coverage Determination (LCD) L32932 Transoral Incisionless Fundoplication for procedure indications.

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

III. DESCRIPTION/BACKGROUND

Transesophageal endoscopic therapies are being developed for the treatment of gastroesophageal reflux disease (GERD). A variety of procedures are being evaluated, including devices for fundoplication, application of radiofrequency (RF) energy, and injection/implantation of prosthetic devices or bulking agents

Due in part to the prevalence of gastroesophageal reflux disease (GERD), there has been interest in creating a minimally invasive transesophageal therapeutic alternative to open or laparoscopic fundoplication or chronic medical therapy. Three types of procedures have been investigated:

1. Transesophageal endoscopic gastroplasty (or gastroplication) is an outpatient procedure. During this procedure, suture(s) are placed in the lower esophageal sphincter. The sutures are designed to strengthen and lengthen the sphincter to decrease reflux.

Currently, three endoscopic suturing devices have received FDA 510(k) marketing clearance for use in treatment of GERD.

- a. EndoCinch™ (CR Bard, Murray Hill, NJ) for partial-thickness plication, approved January 2001
- b. NDO Plicator™ (Ethicon Endo-Surgery, Chicago, IL) for full-thickness plication, approved May 2003
- c. EsophyX™ (EndoGastric Solutions, Redmond, WA) for full-thickness plication, approved September 2007

2. Radiofrequency (RF) energy has been used to produce submucosal thermal lesions at the gastroesophageal junction. (This technique has also been referred to as the Stretta procedure. The CSM Stretta® System [Conway Stuart] received 510(k) marketing clearance from the FDA in 2000 for general use in the electrosurgical coagulation of tissue and intended for use specifically in the treatment of GERD. As of the 2009 policy update, Stretta is manufactured by Mederi Therapeutics.) Specifically, radiofrequency energy is applied through 4 electrodes inserted into the esophageal wall at multiple sites both above and below the squamocolumnar junction. The mechanism of action of the thermal lesions is not precisely known but may be related to ablation of the nerve pathways responsible for sphincter relaxation or may induce a tissue-tightening effect related to heat-induced collagen contraction.

3. Submucosal injection or implantation of a prosthetic or bulking agent to enhance the volume of the lower esophageal sphincter has also been investigated.

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

In one procedure, a biocompatible liquid polymer is injected into the lower esophageal sphincter. On contact with the tissue, the polymer precipitates into a spongy mass. The mechanism of action in reducing reflux is not precisely known. One polymer, Enteryx™, received FDA approval in 2003 through the premarket approval (PMA) process for the treatment of symptomatic GERD. However, on September 23, 2005, Boston Scientific Corporation issued a recall of Enteryx™ due to the device polymerizing shortly after injection into a spongy material that cannot be removed. Serious adverse events involved unrecognized transmural injections of Enteryx™ into structures surrounding the esophagus, potentially resulting in serious injury or death.

Another bulking agent, pyrolytic carbon-coated zirconium oxide spheres (Durasphere®), is being evaluated. Durasphere® is a bulking agent approved for treatment of urinary and fecal incontinence (see policy number 7.01.19). Use of this product for esophageal reflux would be considered off-label use. The website of Carbon Medical Technologies states that Durasphere GR is an investigational device in the U.S. “intended to treat problems associated with GERD.”

The Gatekeeper Reflux Repair System (Medtronic, Shoreview, MN) utilizes a soft, pliable, expandable prosthesis made of a polyacrylonitrile-based hydrogel. The prosthesis is implanted into the esophageal submucosa, and with time, the prosthesis absorbs water and expands, creating bulk in the region of implantation.

Endoscopic submucosal implantation of polymethylmethacrylate beads into the lower esophageal folds has also been investigated

IV. RATIONALE

This policy was based, in part, on a 2003 TEC Assessment of transesophageal endoscopic treatments for gastroesophageal reflux. (1) The TEC Assessment concluded that data were insufficient to permit conclusions about the effects of transesophageal suturing or transesophageal radiofrequency (RF) (the Stretta procedure) on gastroesophageal reflux disease (GERD). Since the 2003 TEC Assessment, this policy has been updated periodically using the MEDLINE database. The most recent literature search was performed for the period of June 2011 through September 2012. Following is a summary of the key literature to date.

A 2005 report of the Agency for Healthcare Research and Quality (AHRQ) on “Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

Disease” found that more efficacy and safety data on new endoscopic approaches were needed. (2) The comparative effectiveness review evaluated studies on the EndoCinch Suturing System, Stretta, Enteryx, and the NDO Plicator. A 2011 update of the AHRQ report (3) excluded Enteryx and the NDO Plicator, since they were no longer available in the U.S., and added the EsophyX® procedure (endoscopic fundoplication), which was commercialized after the 2005 review. The 2011 update reported the following:

- Like the 2005 Comparative Effectiveness Review (CER), the update did not identify any study that compared medical treatment with endoscopic therapy. The strength of evidence was rated insufficient.
 - The review identified one small nonrandomized study that compared laparoscopic total fundoplication with EndoCinch. This study reported that laparoscopic total fundoplication was more effective than EndoCinch in improving GERD symptoms and decreasing acid exposure. The strength of evidence was rated insufficient.
 - No study directly comparing endoscopic treatments was identified for the update. The strength of evidence was rated insufficient.
 - Five cohort studies evaluated the effectiveness of EsophyX®. The proportion of patients who were off proton pump inhibitors (PPIs) at the end of follow-up ranged from 47% to 71%. Significant improvement of quality of life as measured by the GERD-HRQL [health-related quality of life] scale was reported by 2 of the 5 studies. The strength of evidence was rated insufficient.
 - Common adverse events after endoscopic suturing included chest or abdominal pain (up to 24%), bleeding (up to 11%), dysphagia (up to 50%), and bloating (up to 19%). None of these quantitative estimates were reliable because of the lack of a standard definition and uniform system of reporting. The strength of evidence was rated low.

The AHRQ report concluded that for the 3 available endoscopic procedures (EndoCinch™, Stretta™, EsophyX®), effectiveness remains substantially uncertain for the long-term management of GERD. While some clinical benefits were observed in patients who had these procedures, the studies were generally small, of variable quality, and of short duration. In addition, all of these procedures have been associated with complications, including dysphagia, infection/fever, and bloating. Higher quality studies are needed to determine the role and value of endoscopic procedures in the treatment of patients with GERD.

A 2009 systematic review of 33 studies examined 7 endoscopic treatments for GERD (3 of which do not have FDA marketing clearance for use in the U.S.). (4) The review by Chen et al. included sham-controlled and active-controlled studies for the EndoCinch™ suturing system, the Stretta® radiofrequency procedure, and the (recalled) Enteryx™ polymer injection. The authors highlighted the importance of both subjective and

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

objective improvements in GERD studies: To the extent that improved subjective outcomes are mediated by interruption of submucosal sensory fibers from the vagus nerve, ongoing acid reflux may be undetected, leading to adverse consequences. Chen et al. conclude, “Despite the potential benefits of these procedures, there is insufficient evidence at present to establish their safety and efficacy, particularly in the long-term.”

The review of evidence is divided into 3 separate questions, according to the 3 types of procedures included in this policy review:

1. Does transesophageal (transoral) incisionless fundoplication (TIF) improve health outcomes for patients with GERD, compared to treatment with PPIs or laparoscopic fundoplication?
2. Does radiofrequency treatment of the gastroesophageal junction (Stretta procedure) improve outcomes for patients with GERD, compared to treatment with PPIs or to laparoscopic fundoplication?
3. Does endoscopic Injection/Implantation of prosthetics or bulking agents improve outcomes for patients with GERD, compared to treatment with PPIs or laparoscopic fundoplication?

Endoscopic Plication

1. Does TIF improve health outcomes for patients with GERD, compared to treatment with PPIs or laparoscopic fundoplication?

Two early case series reported results of endoscopic plication using non-FDA approved devices. In 1999, Swain reported on a case series of 28 patients with GERD whose symptoms were not controlled with medical therapy. (5) In 2001, Filipi and colleagues reported on a multicenter case series of 64 patients with symptoms of gastroesophageal reflux disease (GERD). (6) These case series were evaluated by the 2003 TEC Assessment, (1) which concluded that these types of studies were insufficient to permit conclusions about the effects of transesophageal suturing on GERD. Randomized, controlled trials (RCTs) were needed to determine the comparative impact on outcomes compared to alternatives, and long-term follow-up data were needed.

EndoCinch™

The available evidence on this question for EndoCinch™ consists of 2 randomized, sham-controlled trials, one non-randomized comparative study, and numerous uncontrolled case series.

Controlled trials. Montgomery et al. reported on a randomized, double-blind sham trial of 46 patients with GERD who required daily PPI therapy in 2006. (7) In this study, 22

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

patients had plication (EndoCinch™) and 24 had a sham procedure. There were no statistically significant differences between groups for some key measures including acid exposure and discontinuation of PPI. Also, there were no changes in the extent of esophagitis. Also noted was a marked loss of sutures, with 67% remaining at 12 months.

Schwartz et al. reported a single-center study of 60 patients with GERD; 20 patients were randomly assigned to EndoCinch™; 20 had a sham procedure; and 20 had observation. (8) At 3-month follow-up, while PPI use decreased more in the active treatment group (compared to sham), there was no difference between the 2 groups in acid exposure time; acid exposure times normalized in 29% of actively treated patients and in 22% of sham patients (p=0.71). During the 12-month follow-up, 29% of those who received suturing were retreated.

In 2006, Mahmood and colleagues reported on a nonrandomized contemporaneous comparative study of 27 patients receiving endoscopic plication with EndoCinch™ to 24 patients having laparoscopic Nissen fundoplication. (9) Many of those receiving endoscopic procedures were referred to a gastroenterologist, while those having the fundoplication were often referred directly to a surgeon. Patients had GERD symptoms requiring continuous PPI treatment; some had breakthrough symptoms on PPIs. In this small, nonrandomized study, symptom control improved in both groups but was better for the Nissen fundoplication group. Dysphagia was more common after Nissen fundoplication. Ninety-one percent of Nissen fundoplication patients achieved normal esophageal pH compared to 48% in the endoscopic group.

A nonrandomized study comparing transesophageal suturing with the EndoCinch™ to laparoscopic antireflux surgery was published in 2004. This comparative study showed that suturing was not as effective as antireflux surgery in reducing medication use. (10)

Uncontrolled studies. There are numerous uncontrolled case series that report on outcomes of EndoCinch treatment. An example is the publication by Mahmood and colleagues, which reported on a case series of 26 patients treated with EndoCinch™ in 2003. (11) This trial reported an improvement in a number of outcome measures, including PPI use, reflux episodes, and heartburn symptoms. However, because of the lack of control group, the clinical meaning of these improvements is unclear.

Other studies. Radiofrequency (RF) has been applied as supplementation to EndoCinch™ plication to reduce the loss of mucosal sutures seen at 1 year with that procedure. In 2008, Mosler et al. (12) reported a pilot study in 16 GERD patients comparing endoluminal gastroplication with EndoCinch alone to EndoCinch with cautery of mucosal surfaces prior to suturing. After 1 year, 10 of 27 sutures (37%) in 9 patients treated with cautery remained intact, while 3 of 20 sutures (15%) in 7 patients treated with EndoCinch alone remained intact. Initial improvements in heartburn, pH score, and medication use were seen at 12 months but were not sustained at 24 months in either group.

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

Several papers have been published on laparoscopic Nissen fundoplication following failed transesophageal endoscopic therapies for GERD. In 2010, Furnee and colleagues reported prospectively collected data from 11 consecutive patients who underwent Nissen fundoplication after failure of EndoCinch™ gastroplication. (13) The 11 patients were from a cohort of 50 (22%) who had been treated with EndoCinch™ from a randomized trial described above (20 randomized to EndoCinch™ and 30 controls who crossed over). (8) Two patients had persistence of their primary symptoms after EndoCinch™ plication, and the other 9 experienced recurrence of symptoms after several months. Upper endoscopy showed disruption of between 1 and 3 of the gastroplications. Nissen fundoplication was performed without major complications at a medium of 23 months (range 7-33) after the EndoCinch™ procedure. After a median follow-up of 31 months (range, 6-61 months), 9 patients (81.8%) reported their preoperative symptoms as resolved or improved. General quality of life improved from 33 to 79 on a visual analog scale (VAS). Three patients (27.3%) had daily complaints of troublesome dysphagia, a rate which compared unfavorably with the 3.6% rate reported after primary Nissen fundoplication. Another patient had troublesome chest pain. Acid exposure times were found to have increased slightly after EndoCinch™ and decreased after Nissen fundoplication.

Conclusions. Comparative studies with EndoCinch™ have failed to show an improvement in acid exposure time when compared to sham and suggest inferior results when compared to laparoscopic surgery. There is a high rate of loss of intact sutures at 1-year follow-up, and there are reports that laparoscopic fundoplication is common following failed EndoCinch™ procedure. A search of the online site www.clinicaltrials.gov in October 2012 found no active trials with EndoCinch™.

Plicator™

The available evidence on Plicator™ consists of 2 RCTs and numerous uncontrolled case series.

Controlled trials. Rothstein et al. reported on use of full-thickness plication (Plicator™) with 3-month follow-up in a randomized, sham-controlled multicenter study of 159 patients with GERD requiring maintenance therapy. (14) In this short-term study, complete cessation of PPI therapy was higher among those in the treatment group than in the sham group (50% vs. 24%, respectively). Quality-of-life scores also improved more in the active group. The percent reduction in median percent time the pH was less than 4 was improved more in the active group (7% vs. 10%, respectively) but did not change in the sham group (10% vs. 9%, respectively). The authors noted that the single full-thickness plication normalized the distal esophageal acid contact for less than one-third of the patients and was not effective in healing esophagitis. Also, radiating shoulder pain and abdominal pain were more frequent adverse events in the active treatment group (12% vs. 0% and 9% vs. 0%, respectively).

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

A small randomized trial from Eastern Europe assigned 52 patients in a 2:1 ratio to transoral incisionless fundoplication (TIF) or to laparoscopic Nissen fundoplication. (15) The first 18 patients randomized to TIF were treated with NDO Plicator™. After the company terminated production of the NDO Plicator™, the next 16 patients randomized to TIF were treated with Esophyx®. Results of this study are described below in the section on Esophyx®.

Uncontrolled case series. Full-thickness fundoplication using the Plicator™ was assessed in a cohort study of 131 patients variably responsive to PPI therapy. (16) At 12 months, 50 patients (38%) were lost to follow-up or had not yet reached their 12-month follow-up visit. Sixty-six percent of the remaining 81 patients demonstrated a 50% reduction in their GERD-Health Related Quality of Life (GERD-HRQL) score, compared to their pre-fundoplication (off meds) score. No serious adverse events were reported. The lack of a contemporaneous control (comparison) group greatly limits the use of these findings.

Use of multiple Plicator™ endoscopic suturing devices was studied in a 12-month industry-supported case series of 41 patients with PPI-dependent GERD. (17) At 12-months, 24 of 41 patients (59%) had discontinued daily PPI therapy. Twenty-six of 41 patients (63%) had an improved GERD-HRQL equal to or greater than 50%. GERD-HRQL scores improved from a median of 25 at baseline *off* PPI to 8 post-treatment, a statistically significant improvement (p<0.001), and from a median of 11 at baseline *on* PPI to 8 post-treatment, a statistically significant improvement (p=0.015). Acid exposure was not measured. All procedure-related adverse events occurred within the first postprocedure week.

A search of online site www.clinicaltrials.gov in October 2012 found several studies with the NDO Plicator listed as terminated, since the sponsoring company (NDO Surgical, Inc.) was acquired by Johnson & Johnson and has ceased business operations.

Esophyx®

The available literature on Esophyx® TIF consists of numerous case series, 1 small randomized controlled trial, 1 small non-randomized study with limited follow-up, and results from a multicenter registry.

Controlled trials. A small randomized trial assigned 52 patients in a 2:1 ratio to TIF (18 NDO Plicator™ and 16 Esophyx®) or to laparoscopic Nissen fundoplication. (15) Patients were enrolled in the study if they had pathologic esophageal acid exposure confirmed by 24-hour pH measurements, responded at least partially to PPI therapy, showed a deteriorated gastroesophageal junction, and had a small hiatal hernia (<2 cm). At the 12-month follow-up, there were 26 patients (76%) in the TIF group and 14 patients (78%) in the Nissen fundoplication group. The GERD-HRQL improved to a similar extent in both groups. At 12 months, a similar percentage of patients in the TIF group (79%) and Nissen fundoplication group (73%) improved in the Hill grade by 50% or more, and the percentage of patients who had completely stopped PPI use was not significantly different

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

(50% TIF vs. 71% Nissen). The hospital stay was significantly shorter following TIF group (2.9 days) compared to Nissen fundoplication (6.4 days).

In 2011, Frazzoni et al. reported a small (n=20) prospective open-label study comparing the EsophyX® procedure with laparoscopic Nissen fundoplication in PPI-resistant patients. (18) Twenty-three of 142 patients who were assessed for persistent heartburn/regurgitation met the criteria for entering the study. Excluded were patients with Barrett’s esophagus, hiatal hernia, previous anti-reflux surgery, progressive systemic sclerosis, severe cardiac/pulmonary disease, or pregnancy. Ten patients with PPI-resistant GERD chose to undergo EsophyX®, and 10 chose laparoscopic fundoplication. There were no significant differences in baseline characteristics between the 2 groups. Ambulatory 24-hour impedance-pH monitoring was performed at baseline and 3 months after fundoplication. Distal and proximal refluxes were significantly reduced in the laparoscopic group (e.g., from a baseline of 73 to 25 at 3 months) but not in the endoscopic group (from 60 to 64). Esophageal acid exposure time was considered to be normal in 100% of cases after Nissen fundoplication versus 50% of cases after EsophyX®. Symptoms, based on a 5-point Likert scale, remained in 0/10 laparoscopically treated patients and 6/10 patients who underwent EsophyX®. Although results from this small comparative study do not support EsophyX® in this select group of patients, randomized trials with a larger number of subjects and longer follow-up are needed to evaluate this procedure.

Registry Data. In 2012, Bell and colleagues reported 6-month follow-up from a prospective multicenter registry of patients with chronic GERD who received TIF using the EsophyX₂ system with SerosaFuse fasteners. (19) For the 100 consecutive patients who were treated in this community-based study, the median GERD symptom duration was 9 years (range, 1-35 years), the median duration of PPI use was 7 years (range, 1-20 years), and 92% of patients had incomplete symptom control despite maximal medical therapy. Fasteners were successfully deployed in 89% of attempted deliveries, and a mean of 20 fasteners were used for fundoplication. Hiatal hernias of 2 cm or less were completely reduced, while those greater than 2 cm were partially reduced. The primary efficacy endpoint at 6-months, the GERD-HRQL score, was normalized (score of 2 or less) in 73% of the 85 patients who had an abnormal GERD-HRQL score before the procedure. Median heartburn scores improved from 18 to 3, regurgitation scores improved from 15 to 0, and reflux symptom index score improved from 24 to 7. The percent of patients using PPIs decreased from 92% of patients before the procedure to 20% of patients after TIF, and an additional 9% of patients continued to use medications but no longer required daily PPI use. The authors noted that although the magnitude of typical symptom improvement was lower with TIF than is expected with traditional Nissen fundoplication, there was a very low incidence of side effects compared to traditional fundoplication.

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

Uncontrolled case series. A 2008 industry-sponsored cohort study of full-thickness (i.e., muscularis) fundoplication (Esophyx®) in 86 PPI-dependent GERD patients reported that 68% of patients discontinued PPI medication use at 12 months. (20) Health-related quality-of-life scores and heartburn scores were significantly different from preprocedure scores *off* PPI but not significantly different from preprocedure scores *on* PPI. Serious adverse events consisted of 2 esophageal perforations and 1 case of postoperative intraluminal bleeding requiring transfusion.

In 2010, Velanovich reported on a series of 24 U.S. patients who underwent endoscopic fundoplication with Esophyx®. (21) Patients considered candidates included those with symptomatic GERD that was responsive to PPIs, a small (<2 cm) hiatal hernia, objective pathologic evidence of GERD, and an absence of other esophageal motility disorders. Four patients had prior Nissen fundoplications with recurrent symptoms. Of the 24 Esophyx® patients, there was 1 major complication with a gastric mucosal tear. At an average 7-week follow-up (range, 6-8 weeks), 13 patients (54%) reported complete resolution of symptoms, and 6 patients (25%) had persistent GERD-related symptoms. The median GERD-HRQL improved from 25 to 5. In a letter to the editor in 2011, Velanovich reported that 2 of these patients subsequently had recurrence of GERD and failure of the Esophyx® fundoplication; the H-fasteners had pulled through the esophagus and were attached to the gastric fundus. (22)

Bell and Freeman reported in 2011 on an industry-funded series of 37 consecutive U.S. patients with PPI-resistant GERD and limited hiatal hernia (33% of patients) who underwent Esophyx® fundoplication. (23) Five patients were reoperations for failed laparoscopic fundoplication. One patient had a complication requiring removal of the fundoplication and was not included in follow-up. At a median 6-month follow-up (range, 3-14 months), no patient reported problems with dysphagia, bloating, or excess flatulence, and 82% were not taking any PPIs. Symptoms were significantly improved compared to baseline on PPIs. Acid exposure was significantly improved and normalized in 61% of patients whose reflux characteristics on PPIs at baseline were elevated. Four patients had an increased acid exposure, 2 of whom underwent revision to laparoscopic Nissen fundoplication.

Barnes and colleagues reported a retrospective study of 124 consecutive patients with PPI-resistant GERD who underwent Esophyx® fundoplication at 2 community hospitals in the U.S. (24) All patients had chronic GERD for a median of 9 years (range 1-35 years) and were on daily double-dose of PPIs for a median of 8 years (range 1-25); 97% reported ineffective symptom control on medical therapy. Of 123 patients treated successfully, 110 (89%) gave consent for follow-up and completed GERD-specific questionnaires (baseline data were based on recall). Five patients underwent laparoscopic Nissen revision and were considered lost to follow-up, rather than treatment failures. Valves in 2 of these 5 patients were reported to have been disrupted due to retching and severe cough. At a median 7-month follow-up (range 5-17 months), typical and atypical symptom scores were

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

normalized (no symptoms) in 75% to 80% of the remaining patients, and PPIs were discontinued by 93%. Endoscopy in 53 patients revealed Hill grade I tight valves in 89% of cases, reduced hiatal hernia in 33/34 (97%), and healed reflux esophagitis in 25/30 (83%). No patient complained of dysphagia or odynophagia. Based on global analysis, 72% of the patients were reported to be in remission, 20% improved symptomatically, and 8% had ongoing GERD. These case series are limited by the short follow-up, lack of control for placebo effects or reporting bias, and lack of objective measures of reflux.

Other studies. Furnee and colleagues reported an increased risk of gastric injury with laparoscopic Nissen fundoplication after failed EsophyX® fundoplication. (25) Of 88 patients in their database who underwent EsophyX® fundoplication, 11 (12.5%) subsequently underwent Nissen fundoplication for persistent (n=7) or recurrent symptoms (n=4) at a mean 8.1 months after the primary procedure. Endoscopy showed partial or total disruption of fasteners in 8 of the 11 patients (72.7%). Nissen fundoplication after EsophyX® resulted in gastric perforation in 2 patients and conversion to laparotomy in 1 patient. Another patient developed a subphrenic abscess requiring surgical exploration. In 7 patients, the preoperative symptoms were resolved or improved after Nissen fundoplication, 3 reported symptom worsening due to new-onset daily dysphagia, and 1 had symptom worsening due to daily heartburn.

Conclusions. The literature on the efficacy of Esophyx® consists of 2 small controlled trials, registry data, and numerous case series. While these studies report improvements in outcomes following treatment with Esophyx, the lack of control group in most of the studies makes the clinical meaning of these changes unclear. Randomized controlled trials with longer follow-up are needed to determine whether Esophyx improves outcomes compared to alternative treatments.

A search of the online site www.clinicaltrials.gov in October 2012 identified 2 Phase III and 2 Phase IV post-marketing studies on EsophyX® sponsored by EndoGastric Solutions. Completion of one of the sham controlled Phase III trials (NCT01110811) was expected in June 2011; no publications have been identified from this study. Completion of the other sham-controlled Phase III trial (NCT01136980) is expected April 2013.

Transesophageal Radiofrequency (i.e., the Stretta Procedure)

2. Does radiofrequency treatment of the gastroesophageal junction (Stretta procedure) improve outcomes for patients with GERD, compared to treatment with PPIs or to laparoscopic fundoplication?

The available evidence consists of a meta-analysis and 4 RCTs, all 4 of which include a sham placebo control, along with numerous uncontrolled case series.

Systematic Review and Meta-analyses. Perry et al. included 20 studies (2 RCTs and 18 case series) with a total of 1,441 patients in their meta-analysis. (26) This review analyzed the within-subjects results following treatment only. The control groups of available

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

clinical trials were not included for comparison. Analysis of the 9 studies (525 patients) that reported subjective heartburn scores showed a significant decrease from 3.55 to 1.19 at a mean of 24.1 months. Analysis of the 9 studies (433 patients) that reported GERD-HRQL showed an improvement from 26.11 to 9.25 at a mean follow-up of 19.8 months. Analysis of the 6 studies (299 patients) that reported short-form (SF)-36 physical component scores showed an improvement from 36.45 to 46.12 at a mean follow-up of 9.5 months. For the 11 studies that measured esophageal pH, significant improvements were found in the Johnson-DeMeester score (from 44.37 to 28.53), the esophageal acid exposure time (from 10.29% to 6.51%), and lower esophageal sphincter pressure (from 16.54 to 20.24). This meta-analysis is limited by the inclusion of lower quality studies and by the analysis, which only examined within-subject differences and did not include between-subjects differences, as reported in the RCTs.

Controlled trials. The 2003 TEC Assessment included one randomized, sham-controlled trial. (27) This trial enrolled patients with symptoms at least partially responsive to PPIs, a pH study showing abnormal acid exposure, and the usual exclusions including severe esophagitis or significant anatomic defect. The sham procedure involved balloon inflation but no needle deployment or energy delivery. A total of 64 patients were randomized, and partial or complete 6-month follow-up data were available on 56 patients.

The results of this trial were inconsistent. Although improvement in heartburn symptoms, quality of life, and general physical quality of life was observed in the active treatment group compared to the sham group, there were no differences in medication usage and esophageal acid exposure. Thus in terms of the objective measures of GERD, the findings are equivocal. The large proportion of sham-treated patients successfully reducing medication use points to possible placebo effect of the procedure. In addition, data are also needed from controlled comparisons with other treatment for GERD, such as Nissen fundoplication, to better characterize outcomes relative to the risks involved.

In 2010, investigators from the U.S. and Egypt reported a 12-month randomized, double-blind, sham-controlled trial to assess RF energy applied to the gastroesophageal junction (i.e., the Stretta procedure). (28) Thirty-six patients with antisecretory medication-dependent GERD for more than 6 months (mean: 7 years) were randomly assigned to receive a single-session RF procedure, a double-session RF procedure for patients who had a less than 75% improvement of GERD-HRQL at 4 months, or a sham procedure. Each patient in the active treatment groups received 56 RF lesions per session. With the double-session group, the authors wished to examine whether 112 lesions created in 2 sessions several months apart were safer than 112 lesions created during a single session, which was the initial “dose” applied during development of the procedure and resulted in esophageal perforation in a few cases. Ten of 12 patients in the double-session group (83%) underwent both sessions.

At 12 months, 2 of 12 patients (17%) in the single-session group, 6 of 12 patients (50%) in the double-session group, and 0 of 12 patients in the sham group had discontinued

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

antisecretory medication therapy. Within group comparisons showed statistically significant improvements in GERD-HRQL in all 3 treatment groups: In the single-session RF group, GERD-HRQL scores improved from a mean of 30 at baseline *off* meds to 14 post-treatment; in the double-session RF group, GERD-HRQL scores improved from 31 to 11; and in the sham group, GERD-HRQL scores improved from 30 to 25. Post-treatment values in the active treatment groups were significantly greater than the sham group ($p < 0.001$) but did not differ from each other ($p > 0.05$). Lower esophageal sphincter pressure increased in the active treatment groups to a statistically significant degree (from 12 mm Hg to 16 mm Hg in the single-session group and from 12 mm Hg to 20 mm Hg in the double-session group; $p < 0.01$ for both groups) but not in the sham group (14 mm Hg at baseline to 16 mm Hg post-treatment, $p > 0.05$). The total time esophageal pH, which was less than 4.2 in a 24-hour period decreased to a statistically significant degree in the active treatment groups (from 9.4 minutes to 6.7 minutes in the single-session group [$p < 0.01$] and from 8.8 minutes to 5.2 minutes in the double-session group [$p < 0.01$]) but not in the sham group (9.9 minutes at baseline to 8.2 minutes post-treatment [$p > 0.05$]). The clinical relevance of these changes is uncertain.

Transient post-procedure adverse events (retrosternal discomfort requiring oral analgesics, mild fever, nausea/vomiting, and dysphagia) were experienced by more patients in the active treatment groups than in the sham groups. Serious adverse events occurred in 1 patient in the single-session group who developed pneumonia and bilateral pleural effusion responsive to 1 week of inpatient antibiotics. Two patients who received double sessions of RF treatment developed prolonged gastroparesis. During 12 months of follow-up evaluation, 1 of these 2 patients showed mild improvement, whereas the other showed no improvement despite high doses of prokinetic medication. The authors speculate that “worsening gastroparesis may be due to vagal injury during Stretta treatment, especially with a greater number of RF lesions.”

Arts and colleagues reported a double-blind randomized cross-over study of Stretta and sham treatment in 22 GERD patients. (29) The initial sham treatment in 11 patients did not affect any of the outcome measures. Three months after the RF procedure, the symptom score was significantly improved (from 14.7 to 8.3), and gastro-esophageal junction compliance was significantly decreased (17.8 vs. 7.4 mL/mm Hg). The quality-of-life score for bodily pain improved from 49.5 to 24.0. No changes were observed in PPI use, esophageal acid exposure, or lower esophageal sphincter pressure after RF. The decrease in compliance of the gastro-esophageal junction was reversed by a smooth muscle relaxant, suggesting that the effect of RF on gastro-esophageal junction compliance was not due to fibrosis.

In an unblinded randomized trial, a total of 43 PPI-dependent GERD patients either continued the effective dose of their PPI or received the RF procedure (Stretta). (30) At 6 months, significantly more patients in the treatment group were able to discontinue or decrease their PPI use by at least 50% than in the control group, a difference that was not

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

maintained at 12 months. Some authors have suggested that PPI discontinuation rather than dose reduction is a more meaningful outcome measure. In this study, the number of patients able to discontinue PPI medication did not differ between groups. Adverse events in the treatment group were described as “transient” and included abdominal pain or epigastric discomfort, odynophagia, and fever. There were no adverse events in the control group.

Uncontrolled studies. The 2003 TEC Assessment (1) evaluated data from 3 case series of 118, 25, and 18 patients, respectively. (31-33) All 3 studies reported improvement in symptoms and symptom-related quality-of-life measures. The largest study reported 12 months’ follow-up (31); the next largest study followed up patients only to 3 months (32); and the smallest study followed up patients to 6 months. (33)

Longer term follow-up of case series have been published. Noar reported on the 4-year follow-up of 109 consecutive patients who underwent the Stretta procedure for drug-refractory GERD. (34) Ninety-six of the 109 patients had results at 4 years; of these, medication use changed from 100% receiving twice daily PPI therapy to 75% eliminating this medication or using it only on an as-needed basis. Quality-of-life scores improved. Thirteen patients required a second procedure. Reymunde and Santiago reported on the 4-year follow-up of 83 consecutive patients with refractory GERD symptoms who were treated using RF energy. (35) Daily medication use dropped from 100% to 14%. Quality-of-life scores improved. However, long-term pH monitoring was not reported in either study.

Radiofrequency for GERD-associated gastroparesis was assessed in a 1-year prospective case series of 31 patients. (36) At 6 months, 23 patients (74%) experienced normalization of gastric emptying. Among this group, GERD–HRQL and dyspepsia symptoms showed significant improvement from baseline (on medication therapy) at 12 months. Among the remaining 8 patients, only GERD-HRQL remained significantly different from baseline (on medication) at 12 months. Minor complications resolved without sequelae and included 4 cases of dyspepsia and 1 case of minor gastric bleeding. There were no serious complications. Reports with small numbers of patients describe preliminary results on use of this procedure in those who have persistent reflux symptoms following antireflux surgery. (37)

Conclusions. Four small RCTs report improvements in symptoms and quality of life following treatment with RF energy. One of the 4 trials reports a reduction in PPI use. Two of the trials also reported a decrease in acid exposure. None of these trials report outcomes past the 12-month time period. Adverse events, including nausea/vomiting, chest pain, dysphagia, and pneumonia have been reported. Larger RCTs with longer follow-up are needed to better define the risks and benefits of this procedure.

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

Injection/Implantation of Prosthetics or Bulking Agents

3. Does endoscopic injection/implantation of prosthetics or bulking agents improve outcomes for patients with GERD, compared to treatment with PPIs or laparoscopic fundoplication?

Enteryx Procedure

The available evidence for this device consists of one RCT and one prospective case series.

Controlled trials. In 2005, Deviere and colleagues reported on a single-blind RCT of 64 patients with GERD randomly assigned to either Enteryx™ implantation or a sham procedure. (38) At 3 and 6 months’ follow-up, patients in the Enteryx™ group had greater reductions in PPI use and more improvement in GERD health-related quality-of-life heartburn scores. However, the small size and short duration of the study limit interpretation of findings.

Uncontrolled case series. The U.S. Food and Drug Administration (FDA) approval for the Enteryx procedure was based on a prospective case series of 85 patients who had GERD that was controlled by medical therapy including PPIs. (39) A successful outcome was defined as elimination of PPI use or a reduction in use of PPIs by at least 50% compared to baseline usage. Therefore, the procedure was clearly designed to be an alternative to medical therapy. At 12 months, 80.3% of the study subjects met the primary outcome. While this case series reports promising results, as noted by the TEC Assessment of other transesophageal endoscopic therapies for GERD, randomized studies are required to determine treatment effectiveness. In fact, as part of the postmarketing phase of FDA regulation, the FDA required a sham-controlled study.

In addition, the long-term efficacy of the implant is unknown. For example, more than 40% of the subjects had a greater than 25% decrease in residual implant volume at 6 and 12 months, raising concerns about the durability of the procedure. The protocol permitted reinjection of the polymer within the first 3 months of therapy; 19 of 85 patients (22%) underwent repeat injection during this period, either due to lack of effectiveness or sloughing of the implanted material. The safety and efficacy of repeat injections are unknown. Other safety concerns include the incidence of retrosternal chest pain immediately postprocedure, reported in 90% of patients. The chest pain resolved within 1 month in 90% of the patients and in all patients by 3 months. A total of 20% of patients reported dysphagia.

In September 2005, Enteryx™ was voluntarily removed from the market due to serious adverse effects.

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

Durasphere

The available evidence for this device consists of one case series. One open-label pilot study (40) of 10 GERD patients injected Durasphere (Carbon Medical Technologies, Saint Paul, MN), a bulking agent approved for treatment of urinary and fecal incontinence, at the gastroesophageal junction. At 12 months, 7 patients (70%) discontinued all antacid medication completely. No erosion, ulceration, or sloughing of material was noted at any injection site.

Gatekeeper Reflux Repair System

The available evidence for this device consists of one RCT. An industry-funded sham-controlled single-blind multicenter study randomized 118 patients into Gatekeeper (n=75) or sham (n=43) treatment. (41) An additional 25 patients were treated as lead-ins during the initial training of investigators and included only in the safety analysis. The patients were implanted initially with 4 Gatekeeper prostheses. At 3 months, 44% of implanted patients received retreatment with up to 4 additional prostheses due to unsatisfactory symptom control. The primary safety endpoint was reduction in serious device- and procedure-related adverse device effects, compared with a surgical procedure composite complication rate of 15%. Four serious adverse events were reported (2 perforations, 1 pulmonary infiltrate related to a perforation, and 1 severe chest pain). The primary efficacy endpoint was reduction in heartburn symptoms using the GERD-HRQL questionnaire. Planned interim analysis after 143 patients were enrolled found that heartburn symptoms and esophageal acid exposure had improved significantly in both the Gatekeeper and sham groups at 6 months, but there was no significant difference between the 2 groups. The study was terminated early due to a lack of efficacy.

Polymethylmethacrylate (PMMA) Beads

The available evidence for this device consists of one case series. A 2001 publication on transesophageal submucosal implantation of polymethylmethacrylate (PMMA) beads consisted of a case series of 10 patients with GERD who were either refractory to or dependent on PPIs. (42) While a significant decrease in symptom scores was noted at post-treatment follow-up (time not specified), the small number of patients and lack of long-term follow-up preclude scientific analysis. No additional studies have been identified evaluating this treatment option.

Clinical Input Received through Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

In response to requests for clinical input on transesophageal incisionless fundoplication using Esophyx, input was received from 2 physician specialty societies and 4 academic medical centers while this policy was under review in 2011. The reviewers agreed that transesophageal incisionless fundoplication is sufficiently different from laparoscopic Nissen fundoplication to warrant evaluation as a separate procedure. The reviewers considered transesophageal incisionless fundoplication (i.e., Esophyx®) to be investigational for the treatment of GERD.

Summary

There is insufficient evidence at present to establish the safety and efficacy of these procedures, particularly in the long term. Some of the unresolved issues include questions about the safety and durability of the device/treatment and lack of consistent improvement in objective measures (esophageal acid exposure) using these devices. A number of these devices (e.g., EndoCinch™, NDO Plicator™, Gatekeeper, Enteryx™) are no longer marketed or actively evaluated due to lack of efficacy and/or safety issues. For procedures that are still in development, high-quality data from large randomized controlled trials are needed to compare endoscopic procedures with both sham controls and with the currently accepted treatments for GERD, namely drug therapy and laparoscopic fundoplication. Well-designed trials should use standardized outcome measures to examine whether subjective improvement, such as discontinuation of medication therapy and GERD-HRQL scores, is supported by objective improvement, such as esophageal acid exposure. Until such studies demonstrate improved net health outcomes for patients with GERD, these techniques are considered investigational.

Practice Guidelines and Position Statements

The American Society of General Surgeons (ASGS) issued a position statement on transoral fundoplication in 2011 stating that “the ASGS supports the use of transoral fundoplication by trained General Surgeons for the treatment of symptomatic chronic gastroesophageal reflux disease (GERD) in patients who fail to achieve satisfactory response to a standard dose of Proton Pump Inhibitor (PPI) therapy or for those who wish to avoid the need for a lifetime of medication dependence.” (43)

The 2008 Medical Position Statement of the American Gastroenterological Association (44) makes no recommendation for or against “the use of currently commercially available endoluminal antireflux procedures in the management of patients with an esophageal syndrome” based on insufficient evidence (Grade Insufficient).

The National Institute for Health and Clinical Excellence of the National Health Service of Great Britain issued interventional procedure guidance in March 2009 and concluded: “The evidence on safety and efficacy of endoscopic radiofrequency (RF) ablation for gastro-oesophageal reflux disease is inadequate and there are inconsistencies in the evidence on efficacy... Therefore, this procedure should only be used with special arrangements for clinical governance, consent and audit or research.” (45) The authors

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

also note that “symptomatic improvement may result from denervation caused by the procedure, making the lower oesophagus insensitive to potentially harmful acid reflux, as opposed to true reflux control.”

2005 guidelines released by the American College of Gastroenterology concluded that systematic reviews of the radiofrequency, endoscopic sewing, and injection techniques were unable to identify any clear indications for these techniques but did support their use in clinical trials and outside of clinical trials in certain well-informed patients who have well-documented GERD that is responsive to proton pump inhibitor (PPI) therapy. (46) Endoscopic therapies for reflux were stated to “control symptoms in selected patients with well-documented GERD,” with level III evidence, which are trials without randomization or single group pre-post, cohort, time series, or matched case-controlled studies. Medical therapy with PPIs and antireflux surgery are endorsed with higher levels of evidence in these guidelines

V. DEFINITIONS

GASTROESOPHAGEAL REFLUX (GERD) is a backflow of contents of the stomach into the esophagus that is often the result of incompetence of the lower esophageal sphincter. Gastric juices are acid and therefore produce burning pain in the esophagus. Repeated episodes of reflux may cause esophagitis, peptic esophageal stricture, or esophageal ulcer.

VI. BENEFIT VARIATIONS

The existence of this medical policy does not mean that this service is a covered benefit under the member's contract. Benefit determinations should be based in all cases on the applicable contract language. Medical policies do not constitute a description of benefits. A member’s individual or group customer benefits govern which services are covered, which are excluded, and which are subject to benefit limits and which require preauthorization. Members and providers should consult the member’s benefit information or contact Capital for benefit information.

VII. DISCLAIMER

Capital’s medical policies are developed to assist in administering a member’s benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member’s benefit information, the benefit information will govern. Capital considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

VIII. REFERENCES

1. *Blue Cross and Blue Shield Association Technology Evaluation Center. Transesophageal Endoscopic Treatments for Gastroesophageal Reflux Disease. TEC Assessment 2003; Volume 18, Tab 20.*
2. *Ip S, Bonis P, Tatsoni A et al. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center Evidence-based Practice Center). AHRQ Publication No. 06-EHC003-EF . Rockville, MD: Agency for Healthcare Research and Quality. 2005. Available online at: <http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=42>. No longer available.*
3. *Ip S, Chung M, Moorthy D et al. Management strategies for gastroesophageal reflux disease: An update. Comparative effectiveness review No. 29 (Prepared by Tufts Medical Center Evidence-based Practice Center under Contract No. HHS 290-2007-10055-I.) AHRQ Publication No. 11-EHC049-EF . Rockville, MD: Agency for Healthcare Research and Quality. 2011. Available online at: <http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=781>. Last accessed October, 2013.*
4. *Humphries LA, Hernandez JM, Clark W et al. Causes of dissatisfaction after laparoscopic fundoplication: the impact of new symptoms, recurrent symptoms, and the patient experience. Surg Endosc 2013; 27(5):1537-45.*
5. *Chen D, Barber C, McLoughlin P et al. Systematic review of endoscopic treatments for gastro-oesophageal reflux disease. Br J Surg 2009; 96(2):128-36.*
6. *Swain CP. Endoscopic suturing. Baillieres Best Pract Res Clin Gastroenterol 1999; 13(1):97-108.*
7. *Filipi CJ, Lehman GA, Rothstein RI et al. Transoral, flexible endoscopic suturing for treatment of GERD: a multicenter trial. Gastrointest Endosc 2001; 53(4):416-22.*
8. *Montgomery M, Hakanson B, Ljungqvist O et al. Twelve months' follow-up after treatment with the EndoCinch endoscopic technique for gastro-oesophageal reflux disease: a randomized, placebo-controlled study. Scand J Gastroenterol 2006; 41(12):1382-9.*
9. *Schwartz MP, Wellink H, Gooszen HG et al. Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial. Gut 2007; 56(1):20-8.*
10. *Mahmood Z, Byrne PJ, McMahon BP et al. Comparison of transesophageal endoscopic plication (TEP) with laparoscopic Nissen fundoplication (LNF) in the treatment of uncomplicated reflux disease. Am J Gastroenterol 2006; 101(3):431-6.*
11. *Chadalavada R, Lin E, Swafford V et al. Comparative results of endoluminal gastroplasty and laparoscopic antireflux surgery for the treatment of GERD. Surg Endosc 2004; 18(2):261-5.*

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

12. Mahmood Z, McMahon BP, Arfin Q et al. Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up. *Gut* 2003; 52(1):34-9.
13. Mosler P, Aziz AM, Hieston K et al. Evaluation of supplemental cautery during endoluminal gastroplication for the treatment of gastroesophageal reflux disease. *Surg Endosc* 2008; 22(10):2158-63.
14. Furnee EJ, Broeders JA, Draaisma WA et al. Symptomatic and objective results of laparoscopic Nissen fundoplication after failed EndoCinch gastroplication for gastro-oesophageal reflux disease. *Eur J Gastroenterol Hepatol* 2010; 22(9):1118-22.
15. Rothstein R, Filipi C, Caca K et al. Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease: A randomized, sham-controlled trial. *Gastroenterology* 2006; 131(3):704-12.
16. Kaindlstorfer A, Koch OO, Antoniou SA et al. A randomized trial on endoscopic full-thickness gastroplication versus laparoscopic antireflux surgery in GERD patients without hiatal hernias. *Surg Laparosc Endosc Percutan Tech* 2013; 23(2):212-22.
17. Svoboda P, Kantorova I, Kozumplik L et al. Our experience with transoral incisionless plication of gastroesophageal reflux disease: NOTES procedure. *Hepatogastroenterology* 2011; 58(109):1208-13.
18. Birk J, Pruitt R, Haber G et al. The Plicator procedure for the treatment of gastroesophageal reflux disease: a registry study. *Surg Endosc* 2009; 23(2):423-31.
19. von Renteln D, Schiefke I, Fuchs KH et al. Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease using multiple Plicator implants: 12-month multicenter study results. *Surg Endosc* 2009; 23(8):1866-75.
20. Frazzoni M, Conigliaro R, Manta R et al. Reflux parameters as modified by EsophyX or laparoscopic fundoplication in refractory GERD. *Aliment Pharmacol Ther* 2011; 34(1):67-75.
21. Bell RC, Mavrelis PG, Barnes WE et al. A Prospective Multicenter Registry of Patients with Chronic Gastroesophageal Reflux Disease Receiving Transoral Incisionless Fundoplication. *J Am Coll Surg* 2012.
22. Muls V, Eckardt AJ, Marchese M et al. Three-year results of a multicenter prospective study of transoral incisionless fundoplication. *Surg Innov* 2013; 20(4):321-30.
23. Barnes WE, Hoddinott KM, Mundy S et al. Transoral Incisionless Fundoplication Offers High Patient Satisfaction and Relief of Therapy-Resistant Typical and Atypical Symptoms of GERD in Community Practice. *Surg Innov* 2011; 18(2):119-29.
24. Cadiere GB, Buset M, Muls V et al. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. *World J Surg* 2008; 32(8):1676-88.
25. Bell RC, Freeman KD. Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal reflux disease. *Surg Endosc* 2011; 25(6):1975-84.

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

26. Velanovich V. *Endoscopic, endoluminal fundoplication for gastroesophageal reflux disease: initial experience and lessons learned. Surgery* 2010; 148(4):646-51; discussion 51-3.
27. Velanovich V. *Re: "Endoscopic, endoluminal fundoplication for gastroesophageal reflux disease: initial experience and lessons learned" by Vic Velanovich, MD, Surgery* 2010;148:646-53. *Surgery* 2011; 149(4):595.
28. Furnee EJ, Broeders JA, Draaisma WA et al. *Laparoscopic Nissen fundoplication after failed EsophyX fundoplication. Br J Surg* 2010; 97(7):1051-5.
29. Perry KA, Banerjee A, Melvin WS. *Radiofrequency Energy Delivery to the Lower Esophageal Sphincter Reduces Esophageal Acid Exposure and Improves GERD Symptoms: A Systematic Review and Meta-analysis. Surg Laparosc Endosc Percutan Tech* 2012; 22(4):283-8.
30. Corley DA, Katz P, Wo JM et al. *Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology* 2003; 125(3):668-76.
31. Aziz AM, El-Khayat HR, Sadek A et al. *A prospective randomized trial of sham, single-dose Stretta, and double-dose Stretta for the treatment of gastroesophageal reflux disease. Surg Endosc* 2010; 24(4):818-25.
32. Arts J, Bisschops R, Blondeau K et al. *A double-blind sham-controlled study of the effect of radiofrequency energy on symptoms and distensibility of the gastro-esophageal junction in GERD. Am J Gastroenterol* 2012; 107(2):222-30.
33. Coron E, Sebillé V, Cadiot G et al. *Clinical trial: Radiofrequency energy delivery in proton pump inhibitor-dependent gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther* 2008; 28(9):1147-58.
34. Triadafilopoulos G, DiBaise JK, Nostrant TT et al. *The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial. Gastrointest Endosc* 2002; 55(2):149-56.
35. Richards WO, Scholz S, Khaitan L et al. *Initial experience with the stretta procedure for the treatment of gastroesophageal reflux disease. J Laparoendosc Adv Surg Tech A* 2001; 11(5):267-73.
36. DiBaise JK, Brand RE, Quigley EM. *Endoluminal delivery of radiofrequency energy to the gastroesophageal junction in uncomplicated GERD: efficacy and potential mechanism of action. Am J Gastroenterol* 2002; 97(4):833-42.
37. Noar MD, Lotfi-Emran S. *Sustained improvement in symptoms of GERD and antisecretory drug use: 4-year follow-up of the Stretta procedure. Gastrointest Endosc* 2007; 65(3):367-72.
38. Reymunde A, Santiago N. *Long-term results of radiofrequency energy delivery for the treatment of GERD: sustained improvements in symptoms, quality of life, and drug use at 4-year follow-up. Gastrointest Endosc* 2007; 65(3):361-6.

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

39. Noar MD, Noar E. Gastroparesis associated with gastroesophageal reflux disease and corresponding reflux symptoms may be corrected by radiofrequency ablation of the cardia and esophagogastric junction. *Surg Endosc* 2008; 22(11):2440-4.

40. McClusky DA, 3rd, Khaitan L, Swafford VA et al. Radiofrequency energy delivery to the lower esophageal sphincter (Stretta procedure) in patients with recurrent reflux after antireflux surgery: can surgery be avoided? *Surg Endosc* 2007; 21(7):1207-11.

41. Deviere J, Costamagna G, Neuhaus H et al. Nonresorbable copolymer implantation for gastroesophageal reflux disease: a randomized sham-controlled multicenter trial. *Gastroenterology* 2005; 128(3):532-40.

42. Johnson DA, Ganz R, Aisenberg J et al. Endoscopic implantation of enteryx for treatment of GERD: 12-month results of a prospective, multicenter trial. *Am J Gastroenterol* 2003; 98(9):1921-30.

43. Ganz RA, Fallon E, Wittchow T et al. A new injectable agent for the treatment of GERD: results of the Durasphere pilot trial. *Gastrointest Endosc* 2009; 69(2):318-23.

44. Fockens P, Cohen L, Edmundowicz SA et al. Prospective randomized controlled trial of an injectable esophageal prosthesis versus a sham procedure for endoscopic treatment of gastroesophageal reflux disease. *Surg Endosc* 2010; 24(6):1387-97.

45. Feretis C, Benakis P, Dimopoulos C et al. Endoscopic implantation of Plexiglas (PMMA) microspheres for the treatment of GERD. *Gastrointest Endosc* 2001; 53(4):423-6.

46. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol* 2013; 108:308–328. Corrigendum. *Am J Gastroenterol* 2013; 108(10):1672. Available online at: <http://gi.org/guideline/diagnosis-and-managemen-of-gastroesophageal-reflux-disease/>. Last accessed October, 2013.

47. Society of American Gastrointestinal and Endoscopic Surgeons. Endoluminal treatments for gastroesophageal reflux disease (GERD). 2013. Available online at: <http://www.sages.org/publications/guidelines/endoluminal-treatments-for-gastroesophageal-reflux-disease-gerd/>. Last accessed October, 2013.

48. American Society of General Surgeons (ASGS). Position statement: Transoral fundoplication. 2011. Available online at: <http://www.theasgs.org/aboutus/ASGS-Transoral-Fundoplication.pdf>. Last accessed October, 2013.

49. American Gastroenterological Association. Medical position statement on the management of gastroesophageal reflux disease. Available online at: <http://www.gastrojournal.org/article/PIIS0016508597701689/related>. Last accessed October, 2013.

50. National Institute for Health and Care Excellence. IPG461 - Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. 2013. Available online at: <http://publications.nice.org.uk/endoscopic-radiofrequency-ablation-for-gastro-oesophageal-reflux-disease-ipg461>. Last accessed October, 2013.

51. National Institute for Health and Care Excellence. IPG404 - Endoluminal gastroplication for gastro-oesophageal reflux disease. 2011. Available online at:

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

http://publications.nice.org.uk/endoluminal-gastropliation-for-gastro-oesophageal-reflux-disease-ipg404/guidance. Last accessed October, 2013.

52. National Institute for Health and Care Excellence. IPG55- Endoscopic injection of bulking agents for gastro-oesophageal reflux disease. 2004. Available online at: <http://publications.nice.org.uk/endoscopic-injection-of-bulking-agents-for-gastro-oesophageal-reflux-disease-ipg55>. Last accessed October, 2013

Other:

Novitas Solutions. Local Coverage Determination ([LCD](#)) [L32932](#) Transoral Incisionless Fundoplicaton. Effective 04/04/13 .

IX. CODING INFORMATION

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational when used for transesophageal endoscopic therapies for gastroesophageal reflux disease; therefore the following are not covered:

CPT Codes ®							
43201	43219	43257	43499				

Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved.

X. POLICY HISTORY

MP 2.053	CAC 2/25/03
	CAC 3/25/03
	CAC 2/24/04
	CAC 5/31/05
	CAC 6/27/06
	CAC 7/31/07
	CAC 7/29/08
	CAC 7/28/09 Consensus Review

MEDICAL POLICY

POLICY TITLE	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE
POLICY NUMBER	MP-2.053

	CAC 5/25/10 Adopted BCBSA Criteria
	CAC 4/26/11 Consensus Review
	CAC 6/26/12 Consensus review. Description/Background updated to match BCBSA changes. Policy statements on biocompatible polymer and PMMA beads combined as bulking agents to match 8/11/11 BCBSA change. Meaning of policy unchanged, references updated.
	CAC 3/26/13 Medicare revision. Medicare variation added to refer to new Novitas LCD) L32932 Transoral Incisionless Fundoplication for procedure indications. References updated.
	03/07/13-Codes reviewed, there is no specific code for the Transesophageal Endoscopic Gastroplasty-sb
	CAC 1/28/14 Consensus review. References updated. No changes to the policy statements. Rationale added.

Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies.